Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Q4 2025 value amounting to 0.48%.

  • Arrowhead Pharmaceuticals' Return on Invested Capital rose 55200.0% to 0.48% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.48%, marking a year-over-year increase of 55200.0%. This contributed to the annual value of 0.16% for FY2025, which is 26600.0% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Return on Invested Capital of 0.48% as of Q4 2025, which was up 55200.0% from 0.1% recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Return on Invested Capital high stood at 0.48% for Q4 2025, and its period low was 5.04% during Q4 2024.
  • Moreover, its 5-year median value for Return on Invested Capital was 0.4% (2022), whereas its average is 0.8%.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Return on Invested Capital tumbled by -37400bps in 2024, and later soared by 55200bps in 2025.
  • Arrowhead Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.48% in 2021, then increased by 18bps to 0.4% in 2022, then tumbled by -228bps to 1.3% in 2023, then crashed by -288bps to 5.04% in 2024, then soared by 109bps to 0.48% in 2025.
  • Its Return on Invested Capital stands at 0.48% for Q4 2025, versus 0.1% for Q3 2025 and 0.17% for Q2 2025.